A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis

BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) often do not tolerate pirfenidone in the recommended dose of 2400 mg/day. The proportion of patients requiring dose reduction and its impact on survival in the real-world remain unclear. METHODS: Consecutive subjects with IPF were enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhooria, Sahajal, Agarwal, Ritesh, Sehgal, Inderpaul Singh, Prasad, Kuruswamy Thurai, Muth, Valliappan, Garg, Mandeep, Bal, Amanjit, Aggarwal, Ashutosh Nath, Behera, Digambar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2020
Materias:
Original Article: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569556/
https://www.ncbi.nlm.nih.gov/pubmed/33093778
http://dx.doi.org/10.36141/svdld.v37i2.8718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569556/
https://www.ncbi.nlm.nih.gov/pubmed/33093778
http://dx.doi.org/10.36141/svdld.v37i2.8718

Ejemplares similares